Lakewood-Amedex Biotherapeutics (LABT) director files Form 3 with zero shares

Rhea-AI Filing Summary

Lakewood-Amedex Biotherapeutics Inc. director Tucker Joseph Edward filed an initial Form 3 reporting his beneficial ownership in the company. The filing lists his direct holdings of common stock at 0 shares following the reporting date, and shows no reported purchases, sales, or option exercises.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tucker Joseph Edward

Role null

Type	Security	Shares	Price	Value
holding	Common Stock; $0.0001 par value	--	--	--

Holdings After Transaction: Common Stock; $0.0001 par value — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Common stock holdings: 0 shares Holding entries: 1 entry Net buy/sell shares: 0 shares

3 metrics

Common stock holdings 0 shares Total shares following transaction on 2026-04-24

Holding entries 1 entry Transaction summary holdingEntries

Net buy/sell shares 0 shares Transaction summary netBuySellShares

Key Terms

Form 3, beneficial ownership, Common Stock; $0.0001 par value

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock; $0.0001 par value financial

""security_title": "Common Stock; $0.0001 par value""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tucker Joseph Edward

(Last) (First) (Middle)

8031 COOPER CREEK BLVD UNIT 103

(Street)

UNIVERSITY PARK FLORIDA 34201

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/24/2026

3. Issuer Name and Ticker or Trading Symbol
Lakewood-Amedex Biotherapeutics Inc. [ LABT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock; $0.0001 par value	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Joseph Tucker	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Lakewood-Amedex Biotherapeutics (LABT) director Tucker Joseph Edward report on his Form 3?

He reports 0 shares of Lakewood-Amedex Biotherapeutics common stock held directly. The Form 3 serves as his initial statement of beneficial ownership and shows no reported purchases, sales, or derivative positions as of the reported date.

How many Lakewood-Amedex Biotherapeutics (LABT) common shares does Tucker Joseph Edward own after the reported Form 3 entry?

The filing shows total direct holdings of 0 shares of common stock following the reported entry. This indicates no directly owned Lakewood-Amedex Biotherapeutics common shares are recorded for him in this initial ownership statement.

Does the Lakewood-Amedex Biotherapeutics (LABT) Form 3 show any insider buying or selling by Tucker Joseph Edward?

No. The Form 3 data show no buy or sell transactions, with buyCount and sellCount both at zero. The entry is categorized as a holding record, reflecting ownership status rather than a new trade in the company’s shares.

What security is reported in Tucker Joseph Edward’s Lakewood-Amedex Biotherapeutics (LABT) Form 3?

The Form 3 covers Common Stock; $0.0001 par value of Lakewood-Amedex Biotherapeutics Inc. The filing indicates his total direct position in this common stock is zero shares following the reported date of the holding entry.

What does the transaction summary show in the Lakewood-Amedex Biotherapeutics (LABT) Form 3 for Tucker Joseph Edward?

The transaction summary reports no buys, no sells, and one holding entry. Net buy-sell shares are zero, and the net buy-sell direction is listed as neutral, indicating the filing only establishes current ownership, not a new transaction.